Servier Group consolidated revenue for the 2022-2023 financial year PAVING THE WAY OF OUR 2030 OBJECTIVES

Servier, an independent international pharmaceutical group, has just published its financial results for the 2022-2023 financial year.


These results was marked by major advances in oncology, confirming the Group’s commitment to developing breakthrough innovations for patients with rare and hard-to-treat cancers.

A scientist in a laboratory works on research - Servier group result 2022 and 2023

Key Highlights

  • Consolidated sales revenue of €5.327 billion, up 9.2% (+12% at CERi) compared to 2021-2022, driven by strong growth in international sales
  • Performance fueled by growth in sales volumes of both brand-name medicines (€4.041 billion, +9.4%) and generics (€1.286 billion, +8.8%)
  • Strong performance in oncology sales, which exceeded the symbolic €1 billion mark
  • Major breakthroughs in oncology, addressing high unmet medical needs
  • A promising and robust R&D pipeline, bringing hope to patients

For more information:

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram